8 completed, 1 terminated, 1 unknown. 4 Phase 2, 4 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Terminated 1, Unknown 1 |
| Phase 3 | 4 | Completed 4 |
| Phase 1 | 2 | Completed 2 |
Follow ObsEva SA: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Pharmacokinetics of Linzagolix in Female Subjects With Normal and Impaired Renal Function Linzagolix - Renal Impairment, Healthy Participants | Phase 1 | Completed | ObsEva SA | 33 | 2019-05-15 | 2020-03-05 |
| Safety and Pharmacokinetics Study of Linzagolix in Female Subjects With Normal and Impaired Hepatic Function Linzagolix - Hepatic Impairment, Healthy Participants | Phase 1 | Completed | ObsEva SA | 24 | 2019-05-15 | 2020-01-13 |
| Study of Nolasiban to Increase Pregnancy Rates in Women Undergoing IVF Nolasiban, Placebo - Infertility | Phase 3 | Completed | ObsEva SA | 820 | 2019-01-10 | 2021-09-09 |
| PoC Study of OBE022 in Threatened Preterm Labour OBE022, Placebos, Atosiban - Preterm Labor | Phase 2 | Unknown | ObsEva SA | 115 | 2018-01-10 | 2021-06-07 |
| Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids OBE2109, Placebo to match OBE2109, Placebo to match Add-back - Uterine Fibroids, Heavy Menstrual Bleeding | Phase 3 | Completed | ObsEva SA | 511 | 2017-05-23 | 2021-03-05 |
| Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids OBE2109, Placebo to match OBE2109, Placebo to match Add-back - Uterine Fibroids, Heavy Menstrual Bleeding | Phase 3 | Completed | ObsEva SA | 526 | 2017-04-20 | 2021-06-09 |
| Phase 3 Placebo Controlled Study of Nolasiban to Improve Pregnancy Rates in Women Undergoing IVF/ICSI Nolasiban 900mg, Placebo - Infertility | Phase 3 | Completed | ObsEva SA | 810 | 2017-03-06 | 2019-12-23 |
| A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis Placebo, OBE2109 - Endometriosis | Phase 2 | Completed | ObsEva SA | 328 | 2016-07-01 | 2022-07-21 |
| A Phase 2 Study of OBE001 Versus Placebo in the Delay of Preterm Birth OBE001, Placebo - Preterm Labor | Phase 2 | Terminated | ObsEva SA | 10 | 2015-03-01 | 2017-11-06 |
| OBE001 Phase 2 Dose-finding Study Versus Placebo in Women Undergoing Embryo Transfer in the Context of IVF-ICSI OBE001 dose 1, OBE001 dose 2, OBE001 dose 3 - Infertility | Phase 2 | Completed | ObsEva SA | 247 | 2014-11-01 | 2017-10-23 |
Infertility (3) · Leiomyoma (2) · Menorrhagia (2) · Obstetric Labor, Premature (2) · Premature Birth (2) · Dysmenorrhea (1) · Dyspareunia (1) · Endometriosis (1) · Hepatic Insufficiency (1) · Kidney Diseases (1) · Liver Diseases (1) · Pelvic Pain (1) · Renal Insufficiency (1)
linzagolix (5) · nolasiban (2) · OBE001 (1) · atosiban (1) · obe022 (1)
Poland (6) · Czechia (5) · Spain (5) · United States (5) · Belgium (4) · Denmark (3) · Germany (3) · Hungary (3) · Russia (3) · Estonia (2) · Finland (2) · Ukraine (2) · United Kingdom (2) · Bulgaria (1) · Canada (1)
PMID 33534895, PMID 36116480, PMID 40326221, PMID 40543832, PMID 32505383, PMID 35947046